Key Drivers
- Very low leverage
- Strong liquidity
- Persistent cash burn
AIAI Summary
Olema has shifted from a pure pre‑commercial, financing‑risk story to an execution‑focused, event‑driven investment where a large cash cushion (~$505M) buys time but makes OPERA‑01 (fall 2026) the decisive make‑or‑break catalyst—investors should treat the stock as a binary trade around that readout rather than a long‑only compounder. Actionable: size positions for high idiosyncratic risk, monitor monthly burn vs guidance, OPERA‑01/OP‑3136 timing, and any partnering moves that could de‑risk commercialization.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Very low leverage
- •Strong liquidity
- •Persistent cash burn
OLMA has minimal debt and strong liquidity but no revenue, large operating losses and negative free cash flow, relying on financing to sustain heavy R&D/SG&A-driven cash burn.
Price Behavior
Key Price Behavior Insights:
- •Price below SMA
- •Large percentage drop
- •Volatility spike
Price is in a clear short-term downtrend — last month's SMA (~$19.70) sits well above the $14.08 close after a ~41.5% fall from ~$24.08, signaling strong negative momentum and a volatility spike in early March.
~41.5% decline from ~$24.08 to $14.08 with early‑March volatility
Sentiment & News
Key News Insights:
- •Phase-3 progress
- •Raised $218.5M
- •Share volatility
Olema strengthened its cash position and advanced Phase 3 programs while attracting a large institutional stake, even as shares plunged and an investor probe added near-term downside risk.
Clinical momentum and a healthier balance sheet underpin medium‑term upside, but near‑term stock performance will likely stay pressured by recent selloffs and the investor probe
Similar Companies in Healthcare
Other companies in the same sector with AI ratings